CLK3 Citations (1)
Originally described in: SGC+yearunpublished
Articles Citing CLK3
| Articles |
|---|
| Type II kinase inhibitors that target Parkinson's disease-associated LRRK2. Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Kramer A, Schwalm MP, Lattal NM, Elson L, Chatterjee D, Mathea S, Hanke T, Leschziner AE, Reck-Peterson SL, Knapp S. Sci Adv. 2025 Jun 6;11(23):eadt2050. doi: 10.1126/sciadv.adt2050. Epub 2025 Jun 4. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.